471 related articles for article (PubMed ID: 16299161)
1. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions.
Ogilvie BW; Zhang D; Li W; Rodrigues AD; Gipson AE; Holsapple J; Toren P; Parkinson A
Drug Metab Dispos; 2006 Jan; 34(1):191-7. PubMed ID: 16299161
[TBL] [Abstract][Full Text] [Related]
2. Studies to further investigate the inhibition of human liver microsomal CYP2C8 by the acyl-β-glucuronide of gemfibrozil.
Jenkins SM; Zvyaga T; Johnson SR; Hurley J; Wagner A; Burrell R; Turley W; Leet JE; Philip T; Rodrigues AD
Drug Metab Dispos; 2011 Dec; 39(12):2421-30. PubMed ID: 21911547
[TBL] [Abstract][Full Text] [Related]
3. Benzylic oxidation of gemfibrozil-1-O-beta-glucuronide by P450 2C8 leads to heme alkylation and irreversible inhibition.
Baer BR; DeLisle RK; Allen A
Chem Res Toxicol; 2009 Jul; 22(7):1298-309. PubMed ID: 19445523
[TBL] [Abstract][Full Text] [Related]
4. Examination of 209 drugs for inhibition of cytochrome P450 2C8.
Walsky RL; Gaman EA; Obach RS
J Clin Pharmacol; 2005 Jan; 45(1):68-78. PubMed ID: 15601807
[TBL] [Abstract][Full Text] [Related]
5. Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast.
Karonen T; Filppula A; Laitila J; Niemi M; Neuvonen PJ; Backman JT
Clin Pharmacol Ther; 2010 Aug; 88(2):223-30. PubMed ID: 20592724
[TBL] [Abstract][Full Text] [Related]
6. An unusual metabolic pathway of sipoglitazar, a novel antidiabetic agent: cytochrome P450-catalyzed oxidation of sipoglitazar acyl glucuronide.
Nishihara M; Sudo M; Kawaguchi N; Takahashi J; Kiyota Y; Kondo T; Asahi S
Drug Metab Dispos; 2012 Feb; 40(2):249-58. PubMed ID: 22028317
[TBL] [Abstract][Full Text] [Related]
7. Underlying mechanism of drug-drug interaction between pioglitazone and gemfibrozil: Gemfibrozil acyl-glucuronide is a mechanism-based inhibitor of CYP2C8.
Takagi M; Sakamoto M; Itoh T; Fujiwara R
Drug Metab Pharmacokinet; 2015 Aug; 30(4):288-94. PubMed ID: 26195223
[TBL] [Abstract][Full Text] [Related]
8. The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo.
Tornio A; Niemi M; Neuvonen M; Laitila J; Kalliokoski A; Neuvonen PJ; Backman JT
Clin Pharmacol Ther; 2008 Sep; 84(3):403-11. PubMed ID: 18388877
[TBL] [Abstract][Full Text] [Related]
9. Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes.
Wang JS; Neuvonen M; Wen X; Backman JT; Neuvonen PJ
Drug Metab Dispos; 2002 Dec; 30(12):1352-6. PubMed ID: 12433802
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.
Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2005 Oct; 97(4):249-56. PubMed ID: 16176562
[TBL] [Abstract][Full Text] [Related]
11. A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement.
Kazmi F; Barbara JE; Yerino P; Parkinson A
Drug Metab Dispos; 2015 Apr; 43(4):523-33. PubMed ID: 25595597
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate.
VandenBrink BM; Foti RS; Rock DA; Wienkers LC; Wahlstrom JL
Drug Metab Dispos; 2011 Sep; 39(9):1546-54. PubMed ID: 21697463
[TBL] [Abstract][Full Text] [Related]
13. An automated cocktail method for in vitro assessment of direct and time-dependent inhibition of nine major cytochrome P450 enzymes - application to establishing CYP2C8 inhibitor selectivity.
Kahma H; Aurinsalo L; Neuvonen M; Katajamäki J; Paludetto MN; Viinamäki J; Launiainen T; Filppula AM; Tornio A; Niemi M; Backman JT
Eur J Pharm Sci; 2021 Jul; 162():105810. PubMed ID: 33753217
[TBL] [Abstract][Full Text] [Related]
14. Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations.
Filppula AM; Laitila J; Neuvonen PJ; Backman JT
Drug Metab Dispos; 2011 May; 39(5):904-11. PubMed ID: 21289076
[TBL] [Abstract][Full Text] [Related]
15. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil.
Shitara Y; Hirano M; Sato H; Sugiyama Y
J Pharmacol Exp Ther; 2004 Oct; 311(1):228-36. PubMed ID: 15194707
[TBL] [Abstract][Full Text] [Related]
16. CYP2C8- and CYP3A-mediated C-demethylation of (3-{[(4-tert-butylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid (CP-533,536), an EP2 receptor-selective prostaglandin E2 agonist: characterization of metabolites by high-resolution liquid chromatography-tandem mass spectrometry and liquid chromatography/mass spectrometry-nuclear magnetic resonance.
Prakash C; Wang W; O'Connell T; Johnson KA
Drug Metab Dispos; 2008 Oct; 36(10):2093-103. PubMed ID: 18653741
[TBL] [Abstract][Full Text] [Related]
17. Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses.
Honkalammi J; Niemi M; Neuvonen PJ; Backman JT
Drug Metab Dispos; 2011 Oct; 39(10):1977-86. PubMed ID: 21778352
[TBL] [Abstract][Full Text] [Related]
18. Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters.
Tornio A; Neuvonen PJ; Niemi M; Backman JT
Expert Opin Drug Metab Toxicol; 2017 Jan; 13(1):83-95. PubMed ID: 27548563
[TBL] [Abstract][Full Text] [Related]
19. CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.
Backman JT; Honkalammi J; Neuvonen M; Kurkinen KJ; Tornio A; Niemi M; Neuvonen PJ
Drug Metab Dispos; 2009 Dec; 37(12):2359-66. PubMed ID: 19773535
[TBL] [Abstract][Full Text] [Related]
20. Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid.
Goosen TC; Bauman JN; Davis JA; Yu C; Hurst SI; Williams JA; Loi CM
Drug Metab Dispos; 2007 Aug; 35(8):1315-24. PubMed ID: 17470524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
